Images List Premium Download Classic


Vaccine-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

NEW Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection
3dt Holdings, Llc
February 15, 2018 - N°20180043015

Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. In an exemplary embodiment of a noninvasive method of screening a cardiac allograft recipient for being at-risk for developing cardiac allograft vasculopathy of the present disclosure, the method comprises the steps of withdrawing at least one biological sample from a cardiac allograft ...
NEW Influenza virus vectors and uses therefor
Flugen, Inc.
February 15, 2018 - N°20180043007

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e. G., as vaccines. The mutant viruses disclosed herein including a mutant m2 sequence are also useful to deliver antigens to a subject, e. G., to induce an ...
NEW Compositions and methods for preventing and treating rhinovirus infections
University Of Virginia Patent Foundation
February 15, 2018 - N°20180043006

An analysis of human cd4+ t-cell epitopes of rv capsid proteins with cross-reactive potential was performed, peptide epitopes of rv-a16 capsid proteins vp1 and vp2 were identified, rv-specific cd4+ t cells were phenotyped for surface markers and cytokine profiles using flow cytometry, and it was found that, among non-infected subjects, circulating rv-a16-specific cd4+ t cells detected at the highest ...
NEW Vaccine Patent Pack
Download + patent application PDFs
Vaccine Patent Applications
Download + Vaccine-related PDFs
For professional research & prior art discovery
  • + full patent PDF documents of Vaccine-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Glycoconjugate vaccine for leishmaniasis
The Board Of Regents Of The University Of Texas System
February 15, 2018 - N°20180043002

Certain embodiments are directed to an immunogenic composition comprising an immunogenic glycoconjugate comprising a glycan having the chemical formula of galactopyranose (galp)-α(1,2)-r, galp-α(1,3)-r, galp-α(1,4)-r, or galp-α(1,6)-r, wherein in r is any monosaccharide, oligosaccharide, or polysaccharide, coupled to a carrier peptide or protein. Certain aspects described herein are ...
Antibody molecules and uses thereof
The University Court Of The University Of Aberdeen
February 08, 2018 - N°20180037640

This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from candida spp. Human antibody encoding genes targeting clinically relevant candida epitopes have been isolated from single b cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant igg1 mabs generated displayed ...
Tuberculosis vaccine compositions and related methods
Board Of Regents, The University Of Texas System
February 08, 2018 - N°20180037616

Compositions and methods directed to esat-6 variants which serve as vaccines for the prevention and prophylactic treatment of tb.
Vaccine Patent Pack
Download + patent application PDFs
Vaccine Patent Applications
Download + Vaccine-related PDFs
For professional research & prior art discovery
  • + full patent PDF documents of Vaccine-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-dengue vaccines and antibodies
Universite Paris-sud
February 08, 2018 - N°20180037611

A dengue virus envelope dimer epitope (ede) wherein the ede: c) spans the polypeptides of a dengue virus envelope polypeptide dimer; and/or d) is presented on a dimer of envelope proteins; and/or c) is formed from consecutive or non-consecutive residues of the envelope polypeptide dimer, wherein the dimer is a homodimer or heterodimer of native and/or mutant ...
Molecular antigen array
Kuros Biosciences Ag
February 08, 2018 - N°20180036399

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in ...
Flavivirus replicons
Novartis Ag
February 08, 2018 - N°20180036398

The invention provides, inter alia, improved replicons and vectors encoding them, where the replicons provide sustained expression of an encoded protein. These replicons comprise flavivirus replicases and heterologous protein coding sequences, wherein the heterologous protein coding sequences are flanked by separation sequences for improved efficacy. These nucleic acids provided by the invention, including self-replicating rnas provided by the invention, are ...
Meningococcal vaccine based on lipooligosaccharide (los) originating from modified neisseria meningitidis strains of immunotype l6
Sanofi Pasteur Sa
February 08, 2018 - N°20180036339

The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by neisseria meningitidis especially of serogroup b. To this end, the invention in particular provides a lipooligosaccharide (lqs) of n. Meningitidis in particular constituted by a lipid a, an inner core, an α chain of l6 or l8 type, in ...
Rna containing compositions and methods of their use
Ecole Normale Superieure
February 08, 2018 - N°20180036334

The present invention relates to a composition comprising an isolated, single stranded rna molecule having a nucleotide sequence comprising 20 or more bases and a pattern of cpg dinucleotides defined by a strength of statistical bias greater than or equal to zero, and a pharmaceutically acceptable carrier suitable for injection. The present invention also relates to a kit comprising a cancer ...
Vaccines based on hepatitis b core antigens
Iqur Limited
February 01, 2018 - N°20180034051

The present invention relates to an electrode composition, to the use of the electrode composition as a cathode and to a lithium-ion cell or battery comprising the electrode composition as a cathode. An electrode composition comprising: a lithium intercalated transition metal oxide or composite thereof in an amount in excess of 80 wt %; an electrochemically exfoliated graphene material; and conductive carbon, ...
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
Sequoia Sciences, Inc
February 01, 2018 - N°20180028648

This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including escherichia coli and multi-drug resistant e. Coli. This invention ...
Vaccine Patent Pack
Download + patent application PDFs
Vaccine Patent Applications
Download + Vaccine-related PDFs
For professional research & prior art discovery
  • + full patent PDF documents of Vaccine-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Zika virus vaccines using virus-like particles
February 01, 2018 - N°20180028643

A flavivirus virus-like particle and methods of making and using that particle, and antibodies raised to a plurality of those particles, are provided.
Toxoid, compositions and related methods
Sanofi Pasteur, Inc.
February 01, 2018 - N°20180028637

The disclosure relates to generally to the field of toxin inactivation. More specifically, it relates to clostridial toxins, methods of inactivating these toxins and compositions (e. G., vaccines) comprising toxoids (e. G., produced by these methods). Provided are methods of producing a c. Difficile toxoid comprising inactivating a c. Difficile toxin with formaldehyde. Toxoids prepared by these methods are stable ...
Immunogenic/therapeutic glycan compositions and uses thereof
Obi Pharma, Inc.
February 01, 2018 - N°20180028629

The present disclosure encompasses immunogenic/therapeutic compositions including globo series antigens (ssea-4, globo h or ssea-3) glycoconjugates and therapeutic adjuvants (obi-821 or obi-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a ssea-4, globo h ...
Thermo-electric heat pump systems
Ambassador Asset Management Limited Partnership
January 25, 2018 - N°20180023865

The disclosure is directed to an energy efficient thermal protection assembly. The thermal protection assembly can comprise three or more thermoelectric unit layers capable of active use of the peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly. The capacitance spacer block is thermally connected between ...
Rabies glycoprotein virus-like particles (vlps)
Novavax, Inc.
January 25, 2018 - N°20180021428

The present invention is generally related to virus-like particles (vlps) comprising rabies virus (rv) glycoproteins (g proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.
Attenuated vaccines to protect against tick-borne ehrlichia species infections
Kansas State University Research Foundation
January 25, 2018 - N°20180021421

Attenuated vaccines to protect vertebrate animals and people against tick-born rickettsial, ehrlichia and anaplasma species infections is disclosed. Also disclosed are methods to modify the organism to achieve the desired immunity through the modification of a novel genetic region involved in pathogenesis. These compounds represent a needed vaccine against an organism causing life-threatening febrile illness in humans and animals, and ...
Novel multivalent nanoparticle-based vaccines
The Usa, As Represented By The Secretary Department Of Health And Human Services
January 25, 2018 - N°20180021258

Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. ...
Method for rapid in vitro synthesis of bioconjugate vaccines via recombinant production of n-glycosylated proteins ...
Cornell University
January 18, 2018 - N°20180016612

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may ...